12:00 AM
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zalviso regulatory update

FDA accepted for review an NDA from AcelRx for Zalviso sufentanil sublingual microtablet system to manage moderate to severe acute pain in a hospital setting. The company submitted the...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >